June 9, 2020
Guerbet's Lipiodol Ultra-Fluid Approved in China for cTACE
June 9, 2020—Guerbet announced that the China National Medical Products Administration has approved an additional indication for Lipiodol Ultra-Fluid for use in conventional transarterial chemoembolization (cTACE) for adult patients with intermediate-stage hepatocellular carcinoma (HCC) in the People's Republic of China.
The company noted that China represents > 50% of all primary liver cancers globally. China has the highest liver cancer prevalence in the world with approximately 330,000 cases, according to the World Health Organization. HCC is the most common primary liver cancer and the fourth biggest cause of death due to cancer worldwide.
In the cTACE procedure, Lipiodol Ultra Fluid mixed with an anticancer drug is injected transarterially in the liver as a locoregional targeted chemotherapy for unresectable HCC. Lipiodol Ultra Fluid acts as a contrast agent, a drug-eluting vehicle, and a dual arterioportal transient embolic.
According to Guerbet, cTACE has been established as the standard-of-care for the treatment of patients with intermediate stage HCC by several international clinical consensus guidelines in China, Japan, South Korea, Europe, and the United States. For interventional oncology procedures, Lipiodol Ultra-Fluid is approved for cTACE indication in numerous countries in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions.